Jungwoo Heparin Injection (Heparin Sodium)
Heparin Sodium
Injections · Prescription medication
JW Pharmaceutical Corporation
MFDS item code 197300034 · Notified 1973.05.14 · Insurance code 644903621
Prevention and treatment of thrombosis, embolism, and atrial fibrillation; diagnosis and treatment of coagulation disorders; inhibition of blood coagulation
This medication is used for the prevention and treatment of thrombosis. It helps prevent and treat thrombosis and pulmonary embolism after surgery, and is effective in preventing and treating embolic atrial fibrillation. It is also used in the diagnosis and treatment of acute and chronic clotting disorders. This drug prevents blood clotting during vascular and cardiac surgery, reducing complications, and is also used to prevent cerebral thrombosis caused by a cerebral hemorrhage. Additionally, it helps prevent blood clotting during transfusions, extracorporeal circulation, and dialysis, and aids in the treatment of coronary artery occlusion and peripheral vascular embolism associated with acute myocardial infarction. Therefore, this drug is used for the prevention and treatment of various thromboembolic diseases.
Usually, this medicine is administered by intravenous injection or added to the blood being perfused during extracorporeal circulation. Although the effect occurs immediately after administration, heparin sensitivity varies widely between individuals. Therefore, perform a heparin sensitivity test before administration, and determine the maintenance dose by measuring blood coagulation time after administration. Usually, after administration, maintain blood coagulation time at 15 ~ 20 minutes or longer, but determine the dose according to the case, indication, and purpose. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Before starting dialysis, administer 1,000 ~ 5,000 IU of heparin sodium. After starting dialysis, administer 500 ~ 1,500 IU per hour continuously or intermittently, with an additional 500 ~ 1,500 IU every hour. (2) Regional heparinization: Administer 1,500 ~ 2,500 IU of this medicine per hour continuously, and neutralize it with protamine sulfate during perfusion in the body. 2) Blood perfusion using a heart-lung machine : Administer 150 ~ 300 IU of this medicine per kg of body weight, and add more as appropriate as the extracorporeal circulation time is extended. After extracorporeal circulation, use protamine sulfate to prevent postoperative bleeding and neutralize the action of heparin. 2. Intravenous drip infusion Dissolve 10,000 ~ 30,000 IU of this medicine in 1,000 mL of 5 % dextrose injection, normal saline injection, or Ringer's solution, and infuse at a rate of approximately 30 drops per minute. When whole blood coagulation time reaches 2 ~ 3 times the pretreatment value, continue the drip infusion at a rate of approximately 20 drops per minute. 3. Intermittent intravenous injection Administer 5,000 ~ 10,000 IU of this medicine intravenously every 4 ~ 8 hours. Starting 3 hours after initiation of administration, measure whole blood coagulation time every 2 ~ 4 hours and adjust the dose to maintain it at 2 ~ 3 times the pretreatment value. 4. Subcutaneous injection Administer 10,000 ~ 20,000 IU of this medicine subcutaneously, followed by a maintenance dose of 15,000 ~ 20,000 IU every 12 hours. Change the injection site with each injection to prevent hematoma. 5. Blood transfusion and blood tests For blood transfusion, use 400 ~ 500 IU of this medicine per 100 mL of blood; for blood tests, use 100 IU per 20 ~ 30 mL of blood.
This medication is a very potent drug and should only be used under the strict supervision of a physician. It should be administered with caution in patients with diseases that have a high risk of bleeding, as this drug can cause bleeding in almost any part of the body. Severe bleeding such as adrenal hemorrhage, ovarian hemorrhage, and retroperitoneal hemorrhage, which can lead to acute adrenal insufficiency, may occur. In addition, the benzyl alcohol component in this drug can cause fatal respiratory problems in premature infants, so it should not be used in newborns or premature babies. It should not be administered to individuals with an allergy to this drug or its components, patients with abnormal coagulation test results, patients with bleeding, patients at high risk of bleeding, patients with severe liver or kidney disease, patients who have recently undergone central nervous system or eye surgery, patients who have received spinal or epidural anesthesia, and patients with a history of thrombocytopenia. Careful administration is required for pregnant women in late pregnancy, children, the elderly, alcoholics, and patients with certain diseases, and coagulation status should be frequently monitored and immediate action taken if abnormalities are found. During the administration of this drug, bleeding symptoms and platelet counts must be closely monitored, and if there is a rapid decrease in platelets, administration should be stopped immediately. If anticoagulant effect is excessively reduced or rapid neutralization of anticoagulation is needed, the antidote protamine sulfate should be used. This drug can interact with other medications, so caution should be exercised particularly when used with analgesics, anti-inflammatory drugs, anticoagulants, and thrombolytics, as there is an increased risk of bleeding. During pregnancy or breastfeeding, special care should be taken due to the risk of bleeding in the uterus and placenta, and the benzyl alcohol component can also affect the fetus and newborn. In cases of overdose, bleeding complications may occur, and an antidote must be administered immediately to neutralize the effects; injection methods that carry a high risk of bleeding, such as intramuscular injection, should be avoided.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a sealed container that can block light if it is for internal use. For export, it should be kept in a sealed container in a cool place below 30 degrees Celsius, taking care not to freeze.
A colorless to pale yellow transparent liquid in a brown glass vial injection
5mL x 10 vials
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Heparin Sodium
Injections · Prescription medication
JW Pharmaceutical Corporation
Heparin Sodium
Prescription medication
Hallym Pharmaceutical Co., Ltd.
Heparin Sodium
Injections · Prescription medication
JW Pharmaceutical Co., Ltd.
Heparin Sodium
Prescription medication
Huons Co., Ltd.
Heparin Sodium
Prescription medication
Huons Co., Ltd.
Heparin Sodium
Injections · Prescription medication
Green Cross Corporation
Heparin Sodium
Prescription medication
Hyun's Co., Ltd.
Heparin Sodium
Prescription medication
BM Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.